How should we intervene in psychosis risk syndromes?

Shanghai Archives of Psychiatry

Volumn 25, Issue 1, 2013, Pages 6-9

  Wang, Jijun ^a   Jiang, Kaida ^a   Zhang, Tianhong ^a   Li, Huijun ^b   Woodberry, Kristen ^c   Seidman, Larry ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FLORIDA A AND M UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876323434     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1002-0829.2013.01.003     Document Type: Review

References (32)

1. Chen E Y, Wong G H, Lam M M, Chiu C P, Hui C L. Real-world implementation of early intervention in psychosis: resources, funding models and evidence-based practice. World Psychiatry 2008; 7(3): 163-164.
2. Addington J. The promise of early intervention. Early Interv Psychiatry 2007; 1(4): 294-307.
3. Wood S. Progressive brain changes across the transition to psychosis: where from here? Schizophr Res 2010; 117(2-3): 112.
4. Giuliano A J, Li H, Mesholam-Gately R I, Sorenson S M, Woodberry K A, Seidman L J. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Current Pharmaceutical Design 2012; 18(4): 399-415.
5. Yung A R, Yuen H P, McGorry P D, Phillips L J, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39(11-12): 964-971
6. Miller T J, McGlashan T H, Woods S W, Stein K, Driesen N, Corcoran C M, et al. Symptom assessment in schizophrenic prodromal states. Psychiatry Quarterly 1999; 70(4): 273-287.
7. Miller T J, McGlashan T H, Rosen J L, Somjee L, Markovich P J, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159(5): 863-865.
8. Cannon T D, Cadenhead K S, Cornblatt B, Woods S W, Addington J, Walker E F, et al. Prediction of psychosis in youth at high clinical risk: a multi-site longitudinal study in North America. Arch General Psychiatry 2008; 65(1): 28-37.
9. Fusar-Poli P, Bonoldi I, Yung A R, Borgwardt S, Kempton M J, Valmaggia L, et al. Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch General Psychiatry 2012; 69(3): 220-229.
10. Correll C U, Hauser M, Auther A M, Cornblatt B A. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry 2010; 51(4): 390-431.
11. Dorph-Petersen K A, Pierri J N, Perel J M, Sun Z, Sampson A R, Lewis D A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30(9): 1649-1661.
12. Konopaske G T, Dorph-Petersen K A, Pierri J N, Wu Q, Sampson A R, Lewis D A. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007; 32(6): 1216-1223.
13. Vernon A C, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011; 69(10): 936-944.
14. Haroun N, Dunn L, Haroun A, Cadenhead K S. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2006; 32(1): 166-178.
15. McGorry P D, Nelson B, Amminger G P, Bechdolf A, Francey S M, Berger G, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70(9): 1206-1212.
16. Morrison A P, French P, Walford L, Lewis S W, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomized controlled trial. Br J Psychiatry 2004; 185: 291-297.
17. Morrison A P, French P, Parker S, Roberts M, Stevens H, Bentall R P, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33(3): 682-687.
18. Bechdolf A, Wagner M, Veith V, Ruhrmann S, Pukrop R, Brockhaus-Dumke A, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry 2007; 1(1): 71-78.
19. Berger G E, Proffitt T M, McConchie M, Yuen H, Wood S J, Amminger G P, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68(12): 1867-1875.
20. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharmacother 2006; 7(7): 837-848.
21. Cornblatt B A, Auther A M, Niendam T, Smith C W, Zinberg J, Bearden C E, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 2007; 33(3): 688-702.
22. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet 2007; 370(9601): 1746-1748.
23. Amminger G P, Schafer M, Papageorgiou K, Harrigan S, McGorry P D, Berger G. Indicated prevention of psychotic disorders with long-chain omega-3 fatty acids: a randomized, placebo-controlled trial. Schizophr Res 2008; 102: S252.
24. Amminger G, Schaefer M R, Papageorgiou K, Becker J, Mossaheb N, Harrigan S M, et al. Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind randomized, placebo-controlled treatment study. Schizophr Bull 2007; 33(2): 418-419.
25. McGlashan T H, Zipursky R B, Perkins D, Addington J, Miller T, Woods S W, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163(5): 790-799.
26. McGorry P D, Yung A R, Phillips L J, Yuen H P, Francey S, Cosgrave E M, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59(10): 921-928.
27. Woods S W, Breier A, Zipursky R B, Perkins D O, Addington J, Miller T J, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54(4): 453-464.
28. Phillips L J, McGorry P D, Yuen H P, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96(1-3): 25-33.
29. Schlosser D A, Miklowitz D J, O'Brien M P, De Silva S D, Zinberg J L, Cannon T D. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry 2012; 6(3): 283-291.
30. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123(1): 30-36.
31. Zheng L, Wang J, Zhang T, Li H, Li C, Jiang K. Reliability and validity of scale of psychosis-risk symptoms (SOPS) in Chinese Version. Chinese Mental Health Journal 2012; 26(8): 571-576. (in Chinese)
32. Cadenhead K S, Addington J, Cannon T, Cornblatt B, McGlashan T, Perkins D, et al. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry 2010; 4(3): 220-226.